This study is planned as a multicenter, randomized, double-blind trial comparing three treatment regimens with respect to their efficacy and safety in preventing the development of MAC bacteremia or disseminated MAC disease in HIV-infected patients with one arm representing each of the single agents Rifabutin and Clarithromycin, and the third arm representing the combination of these two agents.
Showing the most recent 10 out of 767 publications